Drug intelligence / Profile preview

BMD-1231

Development stage: Preclinical
Lead developer: BiologicsMD
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BMD-1231 is an antibody fusion protein drug candidate developed by BiologicsMD. It is currently in preclinical development, with its primary therapeutic focus on skin and musculoskeletal diseases, specifically for the indication of spinal fusion. The detailed mechanism of action and molecular targets have not been publicly disclosed as of the latest available updates.

Beyond the preview

Go deeper on BMD-1231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMD-1231.

Explore the full profile